AWARENESS ABOUT PNEUMOCOCCAL DISEASE DRIVING THE ADOPTION OF CONJUGATE VACCINES
According to the World Health Organization (WHO), pneumococcal disease is the cause of an estimated 1.6 million deaths every year, most of them young children in developing and underdeveloped countries. Pneumococcal disease includes a number of infections caused by different types of pneumococcus bacteria. Currently, there are over 90 different types of such bacteria, and vaccines have been developed to safeguard against them, given that they account for the most number of diseases. These bacteria are the most common cause of pneumonia, which is a severe illness that affects people of all ages. According to WHO, pneumonia resulted in the death of over 920,000 children in 2015, approximately 16% of all deaths of children under the age of five years.
Check out the Research on Global Markets report featured in this article:
The most effective way to safeguard against pneumococcal disease is vaccination. Pneumococcal vaccines are recommended not just for children, but people of all ages who have certain health conditions and are at higher risk of complications arising out of pneumococcal disease. Typically, pneumococcal conjugate vaccines are advised for all children less than two years old. Studies reveal that a single dose of pneumococcal conjugate vaccine is effective in protecting at least 8 in 10 babies from serious infections called invasive pneumococcal disease. Global initiatives are being undertaken to expedite the introduction of pneumococcal conjugate vaccinations in low-income countries through collaborative efforts involving donors, academia, international organizations, and industries. Owing to growing awareness about pneumococcal diseases and the effectiveness of pneumococcal vaccination to prevent the disease, pneumococcal conjugate vaccine held the largest market share (24.66%) in 2017, according to Research on Global Markets.
The introduction of pneumococcal conjugate vaccine has led to a significant reduction in the number of deaths caused by pneumonia over the last decade. These pneumococcal vaccines have witnessed widespread adoption in high-income countries, as well as developing nations. However, more than 40 countries are yet to introduce pneumococcal vaccines. Most of these countries are Asia and Africa - where the occurrence of diseases is the highest, and populations are among the largest, such as China and Nigeria, among others. Awareness about the benefits of pneumococcal conjugate vaccination to prevent life-threatening diseases, coupled with their growing incorporation in the immunisation programmes of emerging economies, bodes well for the global conjugate vaccine market. According to Research on Global Markets, the market is poised to expand at a CAGR of 11.7% till 2022.